of pulmonary nodules; 2) risk assessment for malignancy based on clinical and radiological factors; 3) surveillance of pulmonary nodules; 4) SSNs; 5) biopsy techniques, indications, interpretation, and risks; 6) surgical and nonsurgical treatment; 7) information and support for patients and caregivers; and 8) technical aspects of imaging pulmonary nodules.
Route of detection of pulmonary nodules
It is important to understand whether the management of pulmonary nodules should be tailored according to the route of presentation and clinical context because this may impact on the risk of malignancy. The routes of presentation can be broadly divided into: 1) patients with respiratory symptoms referred for chest X-ray or chest CT; 2) incidental finding on chest X-ray, chest CT, or cross-sectional imaging for other purposes; 3) patients participating in lung cancer screening studies or programs; and 4) patients with known cancer undergoing staging investigations or follow--up imaging.
No studies have directly compared the features of pulmonary nodules according to the route of presentation. The prevalence of nodules in 32 larger case series was found to be greater in CT screening studies (mean, 33%; range, 15%-53%) compared with incidental findings (mean, 15%; range, 2%-14%), but this may reflect the radiological techniques employed and the size threshold for reporting. The prevalence of malignancy was similar (around 1.5%).
An important question is whether nodules detected in the context of a previous history of malignancy are more likely to be cancer. There was surprisingly little consensus here, with some studies suggesting there was no difference, while others showing higher rates of malignancy.
2-5 The reported prevalence of malignancy in coexistent nodules of less than 12 mm in diameter in patients selected to undergo curative surgery was 3% to 11%.
6-8 Key recommendations arising from Figure S1 )
Nodule definitions pulmonary nodule (overall definition)
Focal, rounded opacity ≤3 cm in diameter, mostly surrounded by an aerated lung, including contact with the pleura, but without potentially related abnormalities in the thorax.
subsolid nodule A part-solid or pure ground glass nodule.
part-solid nodule A focal opacity that has both solid and ground glass component ≤3 cm in diameter.
pure ground-glass nodule (synonymous with nonsolid nodule)
A focal ground glass opacity ≤3 cm in diameter that does not obscure a vascular pattern.
definition of applicable terms solid component That part of a nodule that obscures the underlying bronchovascular structure.
ground-glass component Opacification that is greater than that of the background but through which the underlying vascular structure is visible.
For nodules of 300 mm 3 or higher in volume or 8 mm or higher in diameter, the BTS guideline recommends the use of 2 specific composite risk prediction models, the Brock University model 11 and the Herder model. The Brock model showed the highest accuracy for predicting malignancy without positron emission tomography-computed tomography (PET-CT) and was the most accurate for smaller nodules, reflecting the fact that it was developed in a screening cohort. This has also been confirmed in a validation study in a United Kingdom (UK) population. 12 FIGURE 1 shows that patients with nodules that have a probability of malignancy of less than 10%, join the CT surveillance group and those with a higher risk go on to PET-CT, with the findings used to reassess risk using the Herder model, 13 which has the highest accuracy in the CT, as well as investigation of benign or indolent disease, could offset any benefit. Caution is required in patients with a previous history of cancer or active cancer, where the probability of cancer may be higher, and a lower or no threshold for follow-up may be appropriate.
The NELSON study 10 also showed that patients with nodules of 100 to <300 mm 3 in volume had a 2-year risk of lung cancer of 2.4%, and for those with a volume of 300 mm 3 or higher, the risk was 16.9%. The corresponding chance of lung cancer for a nodule of 5 to <8 mm in diameter was 1.0% and for a nodule of 8 mm or higher in diameter-9.7%. The algorithm reflects these findings by showing that for nodules of less than 300 mm 3 in volume or less than 8 mm in diameter, CT surveillance is recommended. the largest transverse cross-sectional diameter. The volume -doubling time (VDT) of a nodule can then be estimated from the difference in the nodule diameter between baseline and follow-up CT and the time interval between the 2 scans, using a simple exponential growth model that assumes uniform 3-dimensional tumor growth. Over the last 15 years, a volumetric analysis (calculated either manually or semiautomated/automated) has been increasingly reported as an alternative and better tool to assess nodule growth. [18] [19] [20] [21] In addition to growth in the size of a nodule, changes in other parameters have been evaluated. De Hoop et al 22 found that mass measurements showed the least intraobserver and interobserver variation. Xu et al 23 showed that malignant nodules increased in density during CT follow-up compared with benign nodules, although there was significant overlap in density changes between benign and malignant nodules.
FIGURE 1 British
Scan interval and growth rate A number of studies have evaluated the scan interval in relation to reliable detection of growth. If automated volumetry is employed, a 3-month interval CT can reliably detect growth, defined as an increase in volume greater than 25%. 20,24-26 However, the accuracy of growth detection diminishes with nodule size so that if diameter measurements are used, the interval for 5-to 6-mm nodules has to be extended to 12 months. The latter may not be an issue except for faster-growing nodules (generally small cell lung cancer and some cases of squamous cell carcinoma).
27-29 A further advantage of a 3-month CT is that the majority of pulmonary nodules that eventually resolve do so after a 3-month interval. 26 The NEL-SON trial 10 showed that stability at 1 year reliably predicts benign disease, but there are no studies that can confirm this for diameter measurements (in the trial even these were semiautomated). Stability over 2 years of follow-up has traditionally been regarded as indicative of benign disease, having first been proposed on the basis of chest X-ray follow-up of nodules in the 1950s, 30 although the evidence underlying this assumption has been questioned.
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FIGURE 2 shows the BTS surveillance algorithm. Reflecting the above evidence, it shows that for nodules of 5 to 6 mm in diameter, a 3-month CT is only indicated if volumetry is performed, and that stability can only be confirmed at 12 months by volumetry. Larger nodules are followed up at 3 months and 12 months with volumetry with a further CT at 24 months if only diameter measurements are available.
The NELSON study 10 also showed that patients with nodules with a VDT of less than 400 days and 400 to 600 days measured after a 3-or 12-month interval, had 2-year cancer probabilities of 9.7% and 4.1%, respectively, significantly greater than the cancer risk of subjects without nodules (0.4%) and the screened population as a whole (1.3%). 10 The 2-year risk of lung cancer UK population (area under the curve, 0.92). 14 In the Herder model, 18 F-fluorodeoxyglucose (FDG) uptake was classified as absent, faint, moderate, or intense. The authors did not provide objective measures or definitions but others have.
15,16 The latter 2 studies used a 5-point scale that the BTS guideline group adapted to a 4-point scale to facilitate consistency in reporting and use with the Herder model (Supplementary material online, Table S1 ). Further management is then guided by risk (<10% surveillance, 10% to 70% biopsy favored and >70% excision or nonsurgical treatment favored, see below).
The Brock model is the only multivariate model that included an analysis of multiple pulmonary nodules. 11 In this model, the presence of multiple nodules had a small negative effect on the likelihood of malignancy in any one nodule. However, BTS-recommended management is governed by the largest nodule, as this was the approach adopted in the NELSON trial. 17 The key recommendations (abbreviated) were: 1 Do not offer nodule follow-up or further workup for people with perifissural or subpleural nodules (homogenous, smooth, solid nodules with a lentiform or triangular shape either within 1 cm of a fissure or the pleural surface and <10 mm in diameter). 2 Consider follow-up of larger intrapulmonary lymph nodes, especially in the presence of a known extrapulmonary primary cancer. 3 Do not offer nodule follow-up for people with nodules of less than 5 mm in diameter or less than 80 mm 3 in volume. 4 Offer CT surveillance to people with nodules of 5 mm or more to less than 8 mm in diameter or 80 mm 3 or more to less than 300 mm 3 in volume. 5 Use the Brock model (full, with spiculation) for initial risk assessment of pulmonary nodules of 8 mm or higher in dimater or 300 mm 3 or higher in volume. 6 Offer a PET-CT in patients with a pulmonary nodule with an initial risk of malignancy of more than 10% where the nodule size is greater than the local PET-CT detection threshold. 7 Following reassessment of risk with the Herder model: consider CT surveillance where the chance of malignancy is less than 10%, image--guided biopsy where the risk is 10% and 70% (other options are excision biopsy or CT surveillance guided by individual risk and patient preference), and surgical resection (or nonsurgical treatment for those who are not fit) as the favored option where the risk is >70%.
Further research validating risk prediction models for nodule malignancy in patients with known extrapulmonary cancer was recommended.
Surveillance of solid pulmonary nodules
The overall aim of surveillance is to use assessment of nodule growth to discriminate between benign and malignant nodules. Pulmonary nodule size has traditionally been assessed by measuring 1 Where initial risk stratification assigns a nodule a chance of malignancy of less than 10%, assess growth rate using interval CT with capability for automated volumetric analysis. 2 Assess growth for nodules of 80 mm 3 or higher in volume or 6 mm or more in the maximum diameter by calculating VDT on the basis of repeat CT at 3 months and 1 year. 3 Use a 25% or higher change in volume to define significant growth. 4 Offer further diagnostic workup (biopsy, imaging, or resection) for patients with nodules showing clear growth or a VDT of less than 400 days (assessed after 3 months and 1 year). 5 Discharge patients with solid nodules that show stability (less than 25% change in volume) on CT after 1 year. 6 If 2-dimensional diameter measurements are used to assess growth, follow up with CT for a total of 2 years. 7 Consider ongoing annual surveillance or biopsy for people with nodules that have a VDT of 400 to 600 days, according to the patient's preference. 8 Where nodules are detected in the context of an extrapulmonary primary cancer, consider the growth rate in the context of the primary and any treatment thereof. was 0.8% when the VDT was longer than 600 days, not achieving significance compared with subjects without nodules (P = 0.06). This is reflected in FIGURE 2, where nodules that have a VDT of more than 400 days are referred for workup, nodules with a VDT of 400 to 600 days are either biopsied or followed further, and those with a VDT of longer than 600 days can be discharged or followed further, depending on the patient's preference and considering their indolent nature.
There is little evidence regarding the management of new nodules that appear in followup CTs, although evidence published since the BTS guideline in an abstract form suggests that new nodules detected in a screening study (NEL-SON 10 ) have an approximate 4% risk of malignancy and hence should be followed closely. Here, the risk of malignancy will depend on the growth rate, and it should be noted that rapid growth may imply an inflammatory process rather than malignancy.
Thus, the BTS recommendations on surveillance of solid nodules differ from those of previous guidelines by recommending volumetry as the preferred method of measurement, reducing the number of follow-up CTs needed and stratifying management on the basis of VDT.
The key recommendations were: baseline volumetric analysis (or diameter measurement if volumetry not available / technically possible)
5-6-mm diameter
thin-section CT, necessary to accurately characterize the nodules. The best evidence for the proportion of SSNs detected that are malignant comes from the Canadian screening trials: in the PanCan dataset, 11 1.9% (21 of 1105) of pGGNs and 6.6% (20 of 303) of PSNs were malignant, and in the British Columbia Cancer Agency, the numbers were lower but the rates were 1.3% (6 of 467) and 22.2% (10 of 45), respectively. Baseline factors consistently associated with malignancy in SSNs are older age, previous history of lung cancer, size of the nodule, and part-solid nature.
11,22,33,34,41-51 The Brock university prediction model also included SSNs and found that although pGGNs are more often malignant than solid nodules, they conferred a lower chance of being malignant when adjusted for other factors in the risk prediction model. However, PSNs were independent predictors of malignancy. Morphological features predictive of malignancy other than initial size were pleural retraction or indentation and a bubble-like appearance in a pGGN. Studies have also shown that around 25% of SSNs resolve after 3 months. PSN) . 32-34 Thus, SSNs may represent preinvasive and invasive lesions, and there are imaging predictors of progression to invasive disease, especially the development of a solid component (which is usually small in relation to the ground-glass component). 35 However, there is some debate about how these lesions should be managed because surgical series have reported a 100% cure rate in nodules that are ground glass in more than 50%. [36] [37] [38] The prevalence of SSNs is difficult to extract from most studies as it is not directly reported, but falls in the range of 2.2% to 3.8% of CTs for pGGN and 0.2% to 1% for PSNs. Standard bronchoscopy has a very low yield but this can be increased with the image-guidance techniques described (fluoroscopy, radial endobronchial ultrasound [EBUS] , and electromagnetic navigation bronchoscopy [ENB], 57 especially in the presence of a CT bronchus sign). The reported yields were 65% to 84% 58-61 for ENB and 46% to 77% for radial EBUS [62] [63] [64] ; lower for lesions of less than 2 cm in diameter in the peripheral third of the lung. This is considerably less than those for CT-guided percutaneous transthoracic biopsy (pooled 91%), although the latter has a much higher pneumothorax rate (6.6% requiring chest drain in the largest series). [65] [66] [67] [68] The latter may be important for some patients, although ENB and, to a lesser extent, radial EBUS may be very time-consuming and are not as widely available as percutaneous biopsy.
CT-guided biopsy was thus identified as the preferred minimally invasive biopsy technique with an average negative likelihood ratio of 0.1. Figure S2 in Supplementary material online shows how the pretest probability of malignancy prior to percutaneous biopsy is altered by a negative biopsy result. This influenced the range of pretest probability of malignancy that appears in the initial assessment algorithm by showing that a biopsy has most influence in the intermediate probability range. There was also evidence that repeat biopsies usually achieved a diagnosis when the first was indeterminate. 68 Variables associated with better CT-guided biopsy performance were nodule size, 69 nodule morphology, 70 needle path length, use of C-arm cone beam system, 71 multiplanar reconstruction, 72 and immediate cytological assessment. 73 The BTS guideline provides greater clarity about the utility of biopsy in indeterminate lesions and specifically recommends repeating the procedure when the first is indeterminate.
Surgical excision biopsy Excision biopsy of pulmonary nodules is performed in 2 situations: first, where clinical suspicion of malignancy remains high despite a benign or indeterminate preoperative biopsy, and second, where a nodule is considered of sufficiently high risk for malignancy to merit the option of excision without an attempt at preoperative biopsy. All of the BTS nodule management algorithms show a place for excision biopsy. This was based on case series that showed this could be done safely and efficiently 74, 75 with some suggestion that waiting times were reduced. The relative performance of thoracoscopic excision wedge biopsy and CT-guided percutaneous lung biopsy were compared in a case series by Mitruka et al. 76 Of 312 patients undergoing CT-guided biopsy, 64% (n = 205) had a malignant diagnosis, 6% (n = 19) had a specific benign diagnosis, and 29% (n = 91) had a nonspecific benign diagnosis. Of the latter group, 47 went on to the excision biopsy group, of which 32 (68%) were malignant. Percutaneous biopsy FIGURE 3 shows the subsolid nodule algorithm of the BTS. After an initial 3-month interval thin-section CT to check whether the SSN is persistent, the Brock model is used to classify nodules into those with a risk of malignancy above or below 10%. It can be seen that imaging follow-up is for a total of 4 years which reflects the slow and intermittent growing nature of these nodules, with VDTs exceeding 1000 days. 44, 45, 48 For nodules with a higher chance of malignancy, a less aggressive approach than for solid nodules is recommended. This is because studies have confirmed the excellent prognosis of these lesions whether first observed or resected immediately.
43-45 Indeed, a small study showed an excellent prognosis without surgery even when cytology was suspicious of malignancy. 52 However, the BTS algorithm does favor resection for larger nodules, for pGGN that enlarge more than 2 mm and those with a new or enlarging solid component. This is also supported by the observation that the size of the solid component is an independent predictor of lymph node metastases, 33 although in 1 large study, 53 no pGGN or PSN with a solid component of 10 mm or less had nodal metastases. PET-CT is not recommended for the routine characterization of SSNs although the sensitivity, specificity, and accuracy of FDG PET-CT is higher for PSN. 54 The key recommendations were: 1 Reassess all SSNs with a repeat thin-section CT at 3 months. 2 Use the Brock risk prediction tool to calculate risk of malignancy in SSNs of 5 mm or higher in diameter that are unchanged at 3 months. 3 Consider using other factors to further refine the estimate of risk of malignancy including smoking status, peripheral eosinophilia, history of lung cancer, size of solid component, bubble--like appearance, and pleural indentation. 4 Consider resection / nonsurgical treatment or observation for pGGN that enlarge 2 mm or more in the maximum diameter; if observed, repeat CT after a maximum of 6 months. Take into account the patient's choice, age, comorbidities, and risk of surgery. 5 Favor resection / nonsurgical treatment over observation for PSN that show enlargement of the solid component or for pGGN that develop a solid component. Take into account the patient's choice, age, comorbidities, and risk of surgery.
Biopsy techniques, indications, interpretation, and risks
Nonsurgical biopsy Nonsurgical biopsy or further nonimaging tests are used where there is sufficient uncertainty about the diagnosis to allow definitive management. The choice of test may depend on the preferences of the patient; therefore, it is especially important to ensure that the balance of accuracy and safety has been explained and that this is acceptable to the patient. The BTS guideline group evaluated a variety of biomarkers and techniques. Some biomarkers showed interesting early results but further studies were latter grouped segmentectomy with wedge resection. 82, 83 There is some nonrandomized low-quality evidence to suggest that segmentectomy is superior to wedge resection in terms of loco-regional recurrence and cancer -related deaths.
82,84,85
Whether segmentectomy is equivalent or inferior to lobectomy is a subject open to debate. In a meta-analysis of 22 studies comparing lobectomy or segmentectomy for stage I lung cancer, segmentectomy was associated with significantly worse survival for stage I tumors (hazard ratio [HR], 1.2; 95% confidence interval [CI], 1.04-1.38) and stage IA tumors (HR, 1.24; 95% CI, 1.08-1.42). 86 However, no difference in survival was seen between these surgical techniques for tumors of 2 cm or smaller in diameter (HR, 1.05; 95% CI, 0.89-1.24). The evidence comparing a lobar versus sublobar resection in SSNs was limited to case series but the excellent survival rate and low rates of recurrence from sublobar resections in these series suggest that there may be little to be gained by extending to a lobectomy. Unfortunately, there was inconsistency in the inclusion criteria reported relating to the cut-off for inclusion of PSNs (eg, >50% ground glass component versus consolidation / tumor ratio of <0.25). Therefore, the recommendation for sublobar resection can only be confidently made for pGGNs.
Localization techniques for pulmonary nodules
If limited resection is planned, nodules that are either of small size, located deep to the visceral pleura, or of ground-glass morphology may be difficult to locate at thoracoscopic surgery. A number of preoperative marking techniques have been developed to facilitate localization of these nodules including CT-guided hookwire 87 / needle 88 / microcoil 89 insertion, lipiodal injection 90 (lipid-soluble contrast medium with subsequent intraoperative fluoroscopy), methylene blue injection 91 (to identify the overlying visceral pleura to guide resection) or radiotracer injection 92 (using technetium-99m macroaggregated albumin with subsequent use of intraoperative gamma probe).
FIGURE 4 shows the BTS treatment algorithm that reflects the key recommendations for optimal surgery for pulmonary nodules listed below: 1 Surgical resection of pulmonary nodules should preferentially be by VATS rather than an open approach. 2 Offer lobectomy as definitive management of a pulmonary nodule confirmed as lung cancer preoperatively or following wedge resection and intraoperative frozen section analysis at the same anesthetic. 3 Consider anatomical segmentectomy where preservation of functioning lung tissue may reduce the operative risk and improve physiological outcome. 4 Consider a diagnostic anatomical segmentectomy for nodules less than 2 cm in diameter without nodal disease when there has been no pathological confirmation and frozen section is not possible.
had an accuracy of 86% for malignant disease and 71% for benign disease, whereas specific diagnoses were achieved for 97% of patients undergoing excision biopsy.
The benign resection rate is critically dependent on the prevalence of malignancy in the population and the quality of preoperative assessment of the probability of malignancy. Benign resection rates in case series of indeterminate pulmonary nodules undergoing surgical excision vary widely from 12% 77 to 86%. 78 Surgical series may not reflect the contemporary world of pulmonary nodules but the recently published UK lung cancer screening study, which adopted a similar protocol to that of the BTS guideline, showed a benign resection rate of only 10%. 79 No studies have specifically addressed the issue of what constitutes an optimal or acceptable benign resection rate. Factors that influence the threshold for surgical resection include the risk of morbidity and mortality for excision (particularly if the nodule turns out to be benign) compared to the possibility of stage progression during a period of radiological surveillance. Inpatient mortality for wedge resection / segmentectomy was reported to be 0.4% by the UK and Ireland Society of Cardio-Thoracic Surgeons (2010; personal communication). The English National Lung Cancer Audit reported a 30-day mortality of 2.1% and a 90-day mortality of 4.2% (35 deaths and 70 deaths, respectively) from 1671 patients undergoing wedge resection or segmentectomy. 80 No accurate estimate of the risk of stage progression during surveillance is available, although the recently published International Association for the Study of Lung Cancer did show survival differences between tumors of less than 1 cm and 1 to 2 cm in diameter. 81 The key recommendations were: 1 Offer percutaneous lung biopsy where the result will alter the management plan. 2 Consider the use of other imaging techniques such as C-arm cone beam CT and multiplanar reconstruction to improve diagnostic accuracy. 3 Interpret negative lung biopsies in the context of the pretest probability of malignancy. 4 Consider repeating percutaneous lung biopsies where the probability of malignancy is high.
Surgical and nonsurgical treatment Optimal surgical treatment Once a decision is made to proceed with surgical excision of a pulmonary nodule, 2 subsequent issues to consider are the surgical approach (video -assisted thoracic surgery [VATS] / thoracotomy) and the extent of the initial lung resection (wedge resection / segmentectomy / lobectomy). The extent of lung resection will also depend on the location of the nodule and the need for lung sparing, but there is also the question of whether sublobar or lobar resection is best. The only prospective randomized controlled trial of lobectomy versus sublobar resection for early stage lung cancer showed more loco-regional recurrence in the sublobar group, the treatments show marked variation in the frequency of harms, something that is likely to be strongly influenced by case selection and technique employed.
FIGURE 4 reflects the key recommendations about nonsurgical treatment as follows: 1 Consider people that are unfit for surgery who have pulmonary nodule(s) with high probability of malignancy, where biopsy is nondiagnostic or not possible, for treatment with SABR or RFA if technically suitable. 2 Consider people that are unfit for surgery who have pulmonary nodule(s) with high probability of malignancy, where biopsy is nondiagnostic or not possible, for treatment with conventional radical radiotherapy if not suitable for SABR or RFA.
Information and support
Patients who have pulmonary nodules detected by whatever method may be concerned or anxious about the implications for their health. A clear understanding is essential for patients and their caregivers to make informed choices about the options for management. They may need professional support when interpreting information, provided, for example, by a lung cancer specialist nurse.
The BTS evidence review found 3 papers of sufficient quality on psychological consequences of the finding of pulmonary nodules. [97] [98] [99] The key findings were that: the finding of a pulmonary nodule has an adverse impact on the quality 5 Use localization techniques depending on local availability and expertise to facilitate limited resection of pulmonary nodules.
Nonsurgical treatment without pathological confirmation FIGURE 4 shows the approach to patients with pulmonary nodules who are judged to be unfit for surgical treatment. This also includes those patients who choose nonsurgical treatment. Where possible, histological confirmation should be attempted but where this is not safe, treatment may proceed without, provided the risk of malignancy is higher than 70%.
Four retrospective cohort studies compared outcomes in patients treated with stereotactic body radiotherapy (SABR) with clinically diagnosed lung cancer versus patients with pathologically proven non-small cell lung cancer. [93] [94] [95] They found similar survival rates although only 3 studies were explicit about potential confounding variables.
The BTS guideline reviewed evidence for several nonsurgical treatments. The majority of evidence found was for SABR and radiofrequency ablation (RFA), although the variability in case definition, pathological confirmation, proportion of primary and secondary cancer, selection criteria, and concomitant treatment made comparison inappropriate. One study used propensity score matching in a comparison of SABR and VATS for stage I-II lung cancer and showed similar 3-year outcomes. 96 Nonsurgical cost -effective approach to the management of pulmonary nodules while encouraging a safe and consistent approach. Although much of the evidence reviewed was recent (a third of the references are from 2012 onwards), it is recognized that ongoing trials may suggest updated guidance is required. For this reason, it is recommended that a record of people with nodules is kept in case a longer-term follow-up is recommended.
Supplementary material online Supplementary material online is available with the online version of the article at www.pamw.pl. of life; patients commonly assume that the finding of a nodule means that they have cancer; patients may be frustrated if health care providers fail to address concerns about cancer or potential adverse effects of surveillance; and effective communication by the health care team can reduce the impact on the quality of life after diagnosis of a pulmonary nodule.
The key recommendations were: 1 Offer accurate and understandable information to patients and caregivers about the probability of malignancy of the pulmonary nodule. 2 Ensure patients have the opportunity to discuss concerns about lung cancer and surveillance regimes. 3 Offer patients the choice of seeing a lung cancer nurse specialist where the probability of malignancy is high or when patients are anxious about the possibility of having lung cancer. 4 Ensure that clear written and verbal information is available on follow-up schedules and the number of repeat CT scans required. 5 Explain the risks and benefits of investigations and treatment. Where appropriate, offer a choice of management.
Technical aspects of the imaging of pulmonary nodules The BTS guideline reviewed evidence for the method of detection, measurement and growth estimation, and factor influencing accuracy. Detection is improved if the maximum section thickness is 1.25 mm 100-102 and reconstruction algorithms such as multiplanar reconstruction, maximum intensity projection, and volume rendering are used. [103] [104] [105] [106] [107] [108] Technical factors that can influence measurement include section thickness, reconstruction algorithm, lung volume, intravenous contrast, and make of software. Patient--related factors include nodule shape, juxta pleural or juxta vascular position, smaller nodule size, and cardiac motion. Low-radiation-dose CT has been shown to produce reliable measurements. 109, 110 The key recommendations were: 1 Where CT scans are performed that include the chest where nodule detection is of potential importance, use a maximum section thickness of 1.25 mm. 2 Use low-radiation-dose CT with a maximum section thickness of 1.25 mm in follow-up imaging. 3 Use maximum intensity projection or volume rendering to improve nodule detection and characterization. 4 When reporting on growth, take into account factors that may reduce accuracy, such as nodule shape and position and interval between scans. 5 Ensure a radiologist or radiographer checks that the nodule has been accurately segmented.
Conclusions
The BTS guideline is primarily aimed to guide clinical practice in the UK but will be applicable in other countries, especially those with similar populations. The significant changes to recommendations should promote a more
